Paradigm Biopharmaceuticals Croissance future

Future contrôle des critères 0/6

Paradigm Biopharmaceuticals devrait augmenter ses bénéfices de 8.8% par an. Le BPA devrait augmenter de 56.9% par an.

Informations clés

8.8%

Taux de croissance des bénéfices

56.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	08 May 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

OTCPK:PBIG.F - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	N/A	-59	-66	-66	N/A
3/31/2024	0	-64	-72	-72	N/A
12/31/2023	0	-69	-78	-78	N/A
9/30/2023	0	-60	-62	-62	N/A
6/30/2023	N/A	-52	-45	-45	N/A
3/31/2023	0	-48	-39	-39	N/A
12/31/2022	0	-44	-33	-33	N/A
9/30/2022	0	-42	-33	-33	N/A
6/30/2022	0	-39	-32	-32	N/A
3/31/2022	0	-40	-32	-32	N/A
12/31/2021	0	-41	-32	-32	N/A
9/30/2021	0	-37	-34	-34	N/A
6/30/2021	0	-34	-35	-35	N/A
3/31/2021	0	-31	-29	-29	N/A
12/31/2020	-1	-28	-24	-23	N/A
9/30/2020	0	-20	-17	-17	N/A
6/30/2020	N/A	-12	-10	-10	N/A
3/31/2020	2	-14	-10	-10	N/A
12/31/2019	4	-16	-10	-10	N/A
9/30/2019	3	-16	-8	-8	N/A
6/30/2019	3	-16	-6	-6	N/A
3/31/2019	3	-11	-7	-7	N/A
12/31/2018	3	-7	-7	-7	N/A
9/30/2018	3	-7	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	2	-6	N/A	-4	N/A
12/31/2017	2	-5	N/A	-3	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-4	N/A	-4	N/A
3/31/2017	2	-4	N/A	-5	N/A
12/31/2016	1	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	1	-3	N/A	-4	N/A
3/31/2016	1	-3	N/A	-3	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PBIG.F devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: PBIG.F devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: PBIG.F devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de PBIG.F devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de PBIG.F devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PBIG.F devrait être élevé dans 3 ans

Paradigm Biopharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance